{
    "ticker": "ABBV",
    "name": "AbbVie Inc.",
    "description": "AbbVie Inc. is a global, research-based biopharmaceutical company formed in 2013 as a spin-off from Abbott Laboratories. Headquartered in North Chicago, Illinois, AbbVie is dedicated to developing innovative medicines that address some of the world's most serious health issues. The company operates in several therapeutic areas, including immunology, oncology, neuroscience, eye care, women's health, and virology. AbbVie's flagship product, Humira, has been a leader in the immunology space, providing relief for patients with conditions such as rheumatoid arthritis and Crohn's disease. With a robust pipeline of new therapies, AbbVie is focused on advancing science to create transformative therapies for patients in need. The company also emphasizes a commitment to sustainability and corporate responsibility, working to reduce its environmental impact and improve access to healthcare worldwide. Through continuous research and development, AbbVie aims to deliver breakthrough treatments that enhance the quality of life for patients and their families.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "North Chicago, Illinois, USA",
    "founded": "2013",
    "website": "https://www.abbvie.com",
    "ceo": "Richard A. Gonzalez",
    "social_media": {
        "twitter": "https://twitter.com/abbvie",
        "linkedin": "https://www.linkedin.com/company/abbvie"
    },
    "investor_relations": "https://investors.abbvie.com",
    "key_executives": [
        {
            "name": "Richard A. Gonzalez",
            "position": "Chairman and CEO"
        },
        {
            "name": "Robert A. Michael",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunology",
            "products": [
                "Humira",
                "Rinvoq",
                "Skyrizi"
            ]
        },
        {
            "category": "Oncology",
            "products": [
                "Imbruvica",
                "Venclexta"
            ]
        },
        {
            "category": "Neuroscience",
            "products": [
                "Duopa",
                "Breztri"
            ]
        }
    ],
    "seo": {
        "meta_title": "AbbVie Inc. | Innovative Biopharmaceuticals",
        "meta_description": "Discover AbbVie Inc., a global biopharmaceutical company dedicated to developing innovative therapies for serious health conditions. Explore AbbVie's commitment to research and patient care.",
        "keywords": [
            "AbbVie",
            "Biopharmaceuticals",
            "Immunology",
            "Oncology",
            "Neuroscience",
            "Health Care"
        ]
    },
    "faq": [
        {
            "question": "What does AbbVie specialize in?",
            "answer": "AbbVie specializes in developing innovative medicines in areas such as immunology, oncology, and neuroscience."
        },
        {
            "question": "Who is the CEO of AbbVie?",
            "answer": "Richard A. Gonzalez is the Chairman and CEO of AbbVie Inc."
        },
        {
            "question": "Where is AbbVie headquartered?",
            "answer": "AbbVie is headquartered in North Chicago, Illinois, USA."
        },
        {
            "question": "What are AbbVie's main products?",
            "answer": "AbbVie's main products include Humira, Imbruvica, and Rinvoq."
        },
        {
            "question": "When was AbbVie founded?",
            "answer": "AbbVie was founded in 2013."
        }
    ],
    "competitors": [
        "JNJ",
        "PFE",
        "MRK",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}